NCT06602726View on ClinicalTrials.gov

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

May 10, 2025

Study Completion Date

August 2, 2025

Conditions

Allergic Conjunctivitis

Interventions

DRUG

REGN1908

Administered per the protocol

DRUG

REGN1909

Administered per the protocol

DRUG

Placebo

Administered per the protocol

Trial Locations (4)

01810

Andover Eye Associates, Andover

K7L 2V7

Kingston Health Sciences Centre, Kingston

K1H 1E4

Red Maple Trials Inc., Ottawa

G1V 4W2

Clinique de Specialisee en Allergie de la Capitale, Québec

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06602726 - A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy | Biotech Hunter | Biotech Hunter